Literature DB >> 8485867

International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material.

S M Marcovina1, J J Albers, L O Henderson, W H Hannon.   

Abstract

In the third phase of the International Federation of Clinical Chemistry (IFCC) study for the standardization of apolipoprotein (apo) measurements, the preparation SP1-01, selected as the candidate international reference material for apo A-I, was investigated for its ability to transfer an accuracy-based value to the immunoassay calibrators and to produce comparability of the values for patients' samples. An apo A-I value of 1.50 g/L (SD 0.08 g/L) was assigned to SP1-01 by a highly standardized RIA calibrated with purified apo A-I for which the mass value had been determined by amino acid analysis. According to a common detailed protocol, the participants transferred the mass value from SP1-01 to the calibrator of each method. To confirm that uniformity of calibration ensures comparability of the values over a wide range of apo A-I values, each laboratory analyzed 50 fresh-frozen samples from individual donors, using an approach similar to that adopted by the Cholesterol Reference Laboratory Network. The consensus mean value for each sample was in excellent agreement with the value assigned by the Northwest Lipid Research Laboratories, with the average absolute bias between assigned and consensus value being 0.01 g/L. The among-laboratory CV on each of the 50 samples ranged from 2.1% to 5.6% (mean 3.6%), demonstrating that comparable apo A-I results can be obtained by a variety of immunochemical methods through the use of certified reference material. Based on the results obtained in these studies, SP1-01 has been approved as Apolipoprotein A-I International Reference Material by the World Health Organization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8485867

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  18 in total

Review 1.  Is it LDL particle size or number that correlates with risk for cardiovascular disease?

Authors:  H Robert Superko; Radhika R Gadesam
Journal:  Curr Atheroscler Rep       Date:  2008-10       Impact factor: 5.113

2.  Associations between abnormal rod-mediated dark adaptation and health and functioning in older adults with normal macular health.

Authors:  Cynthia Owsley; Carrie Huisingh; Gregory R Jackson; Christine A Curcio; Alexander J Szalai; Nassrin Dashti; Mark Clark; Kia Rookard; Mark A McCrory; Tyler T Wright; Michael A Callahan; Lanning B Kline; C Douglas Witherspoon; Gerald McGwin
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

3.  PLTP activity inversely correlates with CAAD: effects of PON1 enzyme activity and genetic variants on PLTP activity.

Authors:  Daniel Seung Kim; Amber A Burt; Jane E Ranchalis; Simona Vuletic; Tomas Vaisar; Wan-Fen Li; Elisabeth A Rosenthal; Weijiang Dong; Jason F Eintracht; Arno G Motulsky; John D Brunzell; John J Albers; Clement E Furlong; Gail P Jarvik
Journal:  J Lipid Res       Date:  2015-05-25       Impact factor: 5.922

4.  Variations in plasma lipid concentration during examination stress.

Authors:  B S McCann; G A Benjamin; C W Wilkinson; J Carter; B M Retzlaff; J Russo; R H Knopp
Journal:  Int J Behav Med       Date:  1996

5.  Evaluation of Lipid Profile and Apolipoproteins in Essential Hypertensive Patients.

Authors:  Parsuram Nayak; Suchismita Panda; Pravat Kumar Thatoi; Roma Rattan; Srikrushna Mohapatra; Pramila Kumari Mishra
Journal:  J Clin Diagn Res       Date:  2016-10-01

Review 6.  The relationship between high density lipoprotein subclass profile and apolipoprotein concentrations.

Authors:  L Tian; M Fu
Journal:  J Endocrinol Invest       Date:  2011-06       Impact factor: 4.256

7.  Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes.

Authors:  S D Sibley; J E Hokanson; M W Steffes; J Q Purnell; S M Marcovina; P A Cleary; J D Brunzell
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

Review 8.  Apolipoprotein A-I and risk for cardiovascular diseases.

Authors:  Natalie Khuseyinova; Wolfgang Koenig
Journal:  Curr Atheroscler Rep       Date:  2006-09       Impact factor: 5.113

9.  Analysis of recently identified dyslipidemia alleles reveals two loci that contribute to risk for carotid artery disease.

Authors:  James Ronald; Ramakrishnan Rajagopalan; Jane E Ranchalis; Julieann K Marshall; Thomas S Hatsukami; Patrick J Heagerty; Gail P Jarvik
Journal:  Lipids Health Dis       Date:  2009-12-01       Impact factor: 3.876

10.  The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls.

Authors:  Sarah Parish; Richard Peto; Alison Palmer; Robert Clarke; Sarah Lewington; Alison Offer; Gary Whitlock; Sarah Clark; Linda Youngman; Peter Sleight; Rory Collins
Journal:  Eur Heart J       Date:  2009-06-11       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.